Bob T. Li
MD, PhD, MPH
Physician Ambassador, Chief Medical Officer
👥Biography 个人简介
Bob Li led the DESTINY-Lung01 and DESTINY-Lung02 trials that established trastuzumab deruxtecan as the first targeted therapy approved for HER2 mutant NSCLC. He is a global authority on HER2 biology in lung cancer and ADC clinical development. His work has redefined treatment of a patient population that historically lacked targeted options.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bob T. Li 的研究动态
Follow Bob T. Li's research updates
留下邮箱，当我们发布与 Bob T. Li（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment